A Trial for the Use of a Pulsed Electromagnetic Field Device to Assist Management of Type 2 Diabetes
NCT ID: NCT04884425
Last Updated: 2021-05-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-06-30
Study Completion Date
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The majority of people with diabetes worldwide consist of type 2 diabetes mellitus. Typically, patients with type 2 diabetes are encouraged to manage their condition with weight loss; healthy eating; regular exercise; blood glucose monitoring; and in some cases, diabetes medication or insulin therapy. However, many struggle with their condition.
Pulsed Electromagnetic Frequency (PEMF) devices, which follow similar principles as a TENS machine, emit electromagnetic fields and are proposed to provide a non-invasive, safe, and easy-to-use method for treatment and management of diabetes related symptoms such as pain, alongside existing treatments and interventions. There is a belief that such devices may promote health and wellbeing and as a result could improve outcomes of type 2 diabetes. The use of the PEMF device would not replace existing treatments, interventions, or any primary care that the participants are currently receiving.
The purpose of this study is to evaluate the effectiveness of a PEMF device of this kind for reported symptoms such as pain, fatigue, and overall wellbeing in people with type 2 diabetes. The study also seeks to explore patients' experiences of using the PEMF device.
Pulsed Electromagnetic Frequency (PEMF) devices, which follow similar principles as a TENS machine, emit electromagnetic fields and are proposed to provide a non-invasive, safe, and easy-to-use method for treatment and management of diabetes related symptoms such as pain, alongside existing treatments and interventions. There is a belief that such devices may promote health and wellbeing and as a result could improve outcomes of type 2 diabetes. The use of the PEMF device would not replace existing treatments, interventions, or any primary care that the participants are currently receiving.
The purpose of this study is to evaluate the effectiveness of a PEMF device of this kind for reported symptoms such as pain, fatigue, and overall wellbeing in people with type 2 diabetes. The study also seeks to explore patients' experiences of using the PEMF device.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pemf Therapy for the Management of Diabetes in Obese Patients
NCT04183543
Obesity
Type 2 Diabetes
UNKNOWN
NA
The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes
NCT00982293
Type 2 Diabetes
TERMINATED
PHASE2
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
NCT07124208
Type 2 Diabetes
RECRUITING
NA
The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy
NCT00134524
Diabetic Neuropathies
Pain
Neuralgia
UNKNOWN
PHASE3
Application of Magnetic Fields as Adjunctive Treatment for Type II Diabetes
NCT00863954
Type II Diabetes Mellitus
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Type 2 diabetes is highly prevalent and many sufferers struggle with their condition. One symptom of type 2 diabetes is diabetic neuropathy, which is characterised by progressive pain and loss of sensation.
Pulsed Electromagnetic Frequency (PEMF) devices, which follow similar principles as a TENS machine, emit electromagnetic fields and are proposed to provide a non-invasive, safe, and easy-to-use method for treatment and management of pain alongside existing treatments and interventions. A recent systematic review reported that pulsed electromagnetic fields had high efficacy in reducing musculoskeletal pain and that methods were well tolerated and had no negative side effects. Research established that pulsed electromagnetic field therapy had beneficial effects on pain, stiffness, and physical function in patients with osteoarthritis. It has, however, been recommended that further research is conducted to examine the use and effectiveness of pulsed electromagnetic field methods.
Given the findings reported regarding the effectiveness of pulsed electromagnetic field methods in reducing pain, it is possible that such devices could prove effective in managing diabetes related symptoms such as pain. It would also be useful to provide insight on the claim that they could potentially improve outcomes of type 2 diabetes and benefit users overall wellbeing.
The study is a pragmatic study as it is considered a better reflection of the perceived clinical benefits in a real world setting as opposed to being more efficacious in a trial setting. Pragmatic studies answer questions such as whether there is perceived additional clinical benefit where a treatment is utilised alongside usual care. This can then determine whether there is reason to explore this matter further and conduct a placebo-controlled trial to further inform health professionals and clinical guidelines.
The purpose of this study, therefore, is to evaluate the effectiveness of a pulsed electromagnetic field (PEMF) device for managing pain, health and wellbeing issues associated with type 2 diabetes via a pragmatic study. The study also seeks to explore patients' experiences of using the device.
Objectives:
1. To evaluate the effectiveness of the PEMF device for symptoms associated with type 2 diabetes.
2. To evaluate the effectiveness of the PEMF device for quality of life in patients with type 2 diabetes.
3. To explore type 2 diabetes patients' experiences of using the PEMF device.
This is a mixed methods study containing quantitative questionnaires and some qualitative interviews. All methods are non-evasive. The target population will be a heterogeneous and demographically diverse group of patients with type 2 diabetes meeting the inclusion criteria. Patients will be aged 18 years and over with a diagnosis of type 2 diabetes. Patients must be willing to participate, be able to read and write in English, and be able to give full, informed, written consent.
Patients will be recruited from patient support groups for adults with type 2 diabetes. In addition, the screening process will exclude those ineligible for inclusion. Responses to an on-line link will highlight the particulars of those interested in participating. Research staff will email an invitation letter to selected respondents (as per the study inclusion criteria ) with type 2 diabetes, together with a screening questionnaire, a patient information sheet and a consent form. Those who indicate they are interested in participating will be further contacted by the research team.
Consenting participants will be randomised into either the PEMF device group or the waiting list control group. There will be 30 participants in the PEMF group and 30 in the waiting list control group. The trial period of device use will last 3 months. Participants will be asked to use the PEMF device for 30 minutes per day.
The study outcome measures will assess diabetes symptoms and quality of life, and will be completed at baseline and at the end of the study intervention. All questionnaire tools have been previously validated. The Interview schedule will be piloted prior to use. Outcome measures consist of the following validated instruments: the Appraisal of Diabetes Scale (ADS), Measure Yourself Medical Outcome Profile (MYMOP)2, and the EQ-5D-5L tool to determine health related quality of life.The outcome measures will be collected at baseline, 6-weeks, 3 months plus a 6 month follow up.
Participants will be asked to complete a patient diary throughout the duration of the trial. The diary will ask participants to indicate use of study interventions, use of prescribed and non-prescribed treatments, and use of NHS services during the course of the trial. The diary will additionally record details of any changes to participants' food consumption during the trial period, device usage, and any routine blood glucose monitoring.
Sociodemographic and treatment characteristics will be obtained from a participants demographics questionnaire. These will include gender, age, educational level, marital status, and diabetes treatment received and dosage.
Participants will be invited to send the study team any clinical result sheets from participants' routine care. Such results routinely include glycated haemoglobin level (HbA1c) systolic/diastolic blood pressure, total cholesterol, low-density lipoprotein cholesterol (LDL), high density lipoproteins (HDL), and triglycerides. Any such information will be analysed and where appropriate help to address the research questions.
No restrictions will be placed on the care provided by healthcare professionals treating participants but use of prescribed and non-prescribed treatments will be recorded.
Members of the PEMF device group will be invited to qualitative on-line focus groups or interviews. Participants will also be asked to participate in focus groups to explore their experiences of using the PEMF device, including participants' perceptions on how the device could be improved, any perceived impact on their diabetes and quality of life, and any adverse effects. Focus groups were chosen as the data-gathering method of choice, as the interaction helps participants to explore and refine their own experiences and perspectives. Two members of the research team will jointly conduct each focus group. The focus groups will be directed by a topic guide. Topic guides will be updated throughout the study to incorporate emerging themes. Focus groups will take place 3 months after the initiation of the PEMF intervention. Up to 5 focus groups will take place with patients using the PEMF device. Focus groups will be audio-recorded and transcribed verbatim.
The PEMF devices will be delivered to the homes of participants and all measures involve self-reporting to be conducted at participants' own homes.
Project milestones:
Milestone 1: Pre-study preparation (2 months)
* produce study documents (information sheets, consent forms)
* obtain ethical approval
Milestone 2: Recruitment/ data collection (6 months)
* recruitment of 60 patients to the study
* obtain all baseline and follow-up outcome measures
* complete all focus groups
* mid-term report to study funders
Milestone 3: Data analysis (2 months)
* statistical analysis of data from outcome measures
* analysis of data from qualitative focus groups
Milestone 4: Dissemination
* end of study report to funders
* dissemination of findings to participants
* dissemination through conferences and peer reviewed journal articles
Data analysis-
Quantitative data- Appropriate descriptive statistics will be estimated for all baseline sociodemographic and clinical variables by arm, and for outcome variables (scores on). The association between baseline sociodemographic or clinical variables and outcome variables will be assessed using appropriate between-group tests or correlations depending on skewness. Primary outcome variables will be compared between the arms using t-tests, one-way analysis of variance, Mann-Whitney tests and Kruskal-Wallis tests, bearing in mind any skewness in the data. Data will also evaluate the impact of medication on outcome, comparing treatment outcomes from those on diabetic medication compared to those not currently receiving medication for their diabetes. An intention-to-treat analysis model will be followed.
Qualitative data- Data will be analysed inductively, using thematic analysis. One of the researchers will immerse themselves in the data, repeatedly reading the transcripts to understand participants' experiences. Key issues, concepts and themes arising from the data will be identified to create a coding framework. Transcripts will then be coded and analysed thematically.
Pulsed Electromagnetic Frequency (PEMF) devices, which follow similar principles as a TENS machine, emit electromagnetic fields and are proposed to provide a non-invasive, safe, and easy-to-use method for treatment and management of pain alongside existing treatments and interventions. A recent systematic review reported that pulsed electromagnetic fields had high efficacy in reducing musculoskeletal pain and that methods were well tolerated and had no negative side effects. Research established that pulsed electromagnetic field therapy had beneficial effects on pain, stiffness, and physical function in patients with osteoarthritis. It has, however, been recommended that further research is conducted to examine the use and effectiveness of pulsed electromagnetic field methods.
Given the findings reported regarding the effectiveness of pulsed electromagnetic field methods in reducing pain, it is possible that such devices could prove effective in managing diabetes related symptoms such as pain. It would also be useful to provide insight on the claim that they could potentially improve outcomes of type 2 diabetes and benefit users overall wellbeing.
The study is a pragmatic study as it is considered a better reflection of the perceived clinical benefits in a real world setting as opposed to being more efficacious in a trial setting. Pragmatic studies answer questions such as whether there is perceived additional clinical benefit where a treatment is utilised alongside usual care. This can then determine whether there is reason to explore this matter further and conduct a placebo-controlled trial to further inform health professionals and clinical guidelines.
The purpose of this study, therefore, is to evaluate the effectiveness of a pulsed electromagnetic field (PEMF) device for managing pain, health and wellbeing issues associated with type 2 diabetes via a pragmatic study. The study also seeks to explore patients' experiences of using the device.
Objectives:
1. To evaluate the effectiveness of the PEMF device for symptoms associated with type 2 diabetes.
2. To evaluate the effectiveness of the PEMF device for quality of life in patients with type 2 diabetes.
3. To explore type 2 diabetes patients' experiences of using the PEMF device.
This is a mixed methods study containing quantitative questionnaires and some qualitative interviews. All methods are non-evasive. The target population will be a heterogeneous and demographically diverse group of patients with type 2 diabetes meeting the inclusion criteria. Patients will be aged 18 years and over with a diagnosis of type 2 diabetes. Patients must be willing to participate, be able to read and write in English, and be able to give full, informed, written consent.
Patients will be recruited from patient support groups for adults with type 2 diabetes. In addition, the screening process will exclude those ineligible for inclusion. Responses to an on-line link will highlight the particulars of those interested in participating. Research staff will email an invitation letter to selected respondents (as per the study inclusion criteria ) with type 2 diabetes, together with a screening questionnaire, a patient information sheet and a consent form. Those who indicate they are interested in participating will be further contacted by the research team.
Consenting participants will be randomised into either the PEMF device group or the waiting list control group. There will be 30 participants in the PEMF group and 30 in the waiting list control group. The trial period of device use will last 3 months. Participants will be asked to use the PEMF device for 30 minutes per day.
The study outcome measures will assess diabetes symptoms and quality of life, and will be completed at baseline and at the end of the study intervention. All questionnaire tools have been previously validated. The Interview schedule will be piloted prior to use. Outcome measures consist of the following validated instruments: the Appraisal of Diabetes Scale (ADS), Measure Yourself Medical Outcome Profile (MYMOP)2, and the EQ-5D-5L tool to determine health related quality of life.The outcome measures will be collected at baseline, 6-weeks, 3 months plus a 6 month follow up.
Participants will be asked to complete a patient diary throughout the duration of the trial. The diary will ask participants to indicate use of study interventions, use of prescribed and non-prescribed treatments, and use of NHS services during the course of the trial. The diary will additionally record details of any changes to participants' food consumption during the trial period, device usage, and any routine blood glucose monitoring.
Sociodemographic and treatment characteristics will be obtained from a participants demographics questionnaire. These will include gender, age, educational level, marital status, and diabetes treatment received and dosage.
Participants will be invited to send the study team any clinical result sheets from participants' routine care. Such results routinely include glycated haemoglobin level (HbA1c) systolic/diastolic blood pressure, total cholesterol, low-density lipoprotein cholesterol (LDL), high density lipoproteins (HDL), and triglycerides. Any such information will be analysed and where appropriate help to address the research questions.
No restrictions will be placed on the care provided by healthcare professionals treating participants but use of prescribed and non-prescribed treatments will be recorded.
Members of the PEMF device group will be invited to qualitative on-line focus groups or interviews. Participants will also be asked to participate in focus groups to explore their experiences of using the PEMF device, including participants' perceptions on how the device could be improved, any perceived impact on their diabetes and quality of life, and any adverse effects. Focus groups were chosen as the data-gathering method of choice, as the interaction helps participants to explore and refine their own experiences and perspectives. Two members of the research team will jointly conduct each focus group. The focus groups will be directed by a topic guide. Topic guides will be updated throughout the study to incorporate emerging themes. Focus groups will take place 3 months after the initiation of the PEMF intervention. Up to 5 focus groups will take place with patients using the PEMF device. Focus groups will be audio-recorded and transcribed verbatim.
The PEMF devices will be delivered to the homes of participants and all measures involve self-reporting to be conducted at participants' own homes.
Project milestones:
Milestone 1: Pre-study preparation (2 months)
* produce study documents (information sheets, consent forms)
* obtain ethical approval
Milestone 2: Recruitment/ data collection (6 months)
* recruitment of 60 patients to the study
* obtain all baseline and follow-up outcome measures
* complete all focus groups
* mid-term report to study funders
Milestone 3: Data analysis (2 months)
* statistical analysis of data from outcome measures
* analysis of data from qualitative focus groups
Milestone 4: Dissemination
* end of study report to funders
* dissemination of findings to participants
* dissemination through conferences and peer reviewed journal articles
Data analysis-
Quantitative data- Appropriate descriptive statistics will be estimated for all baseline sociodemographic and clinical variables by arm, and for outcome variables (scores on). The association between baseline sociodemographic or clinical variables and outcome variables will be assessed using appropriate between-group tests or correlations depending on skewness. Primary outcome variables will be compared between the arms using t-tests, one-way analysis of variance, Mann-Whitney tests and Kruskal-Wallis tests, bearing in mind any skewness in the data. Data will also evaluate the impact of medication on outcome, comparing treatment outcomes from those on diabetic medication compared to those not currently receiving medication for their diabetes. An intention-to-treat analysis model will be followed.
Qualitative data- Data will be analysed inductively, using thematic analysis. One of the researchers will immerse themselves in the data, repeatedly reading the transcripts to understand participants' experiences. Key issues, concepts and themes arising from the data will be identified to create a coding framework. Transcripts will then be coded and analysed thematically.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type 2 Diabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Consenting participants will be randomised into either the PEMF device group or the waiting list control group. There will be 30 participants in the PEMF group and 30 in the waiting list control group.
Primary Study Purpose
SUPPORTIVE_CARE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PEMF Device Group
This arm will consist of participant's who have been randomly assigned to use the PEMF device daily for 30 mins for an overall 3 months
Group Type
ACTIVE_COMPARATOR
Pulsed Electromagnetic Frequency Device (Energy5)
Intervention Type
DEVICE
A pulsed electromagnetic frequency (PEMF) device which is recommended to be used for 30 minutes a day
Waiting List Control Group
These participants will be randomly selected to be on the waiting list group. All waiting list participants will be offered the use of the PEMF device after the study has completed
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pulsed Electromagnetic Frequency Device (Energy5)
A pulsed electromagnetic frequency (PEMF) device which is recommended to be used for 30 minutes a day
Intervention Type
DEVICE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Energy5
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-65 years, of any gender.
* Consulted at their general practice for type 2 diabetes in the previous 12 months.
* Residing within England (due to delivery difficulties from covid-19).
* Self-reported confirmed diagnosis of type 2 diabetes.
* Self-reported stable medication regime for diabetes for at least one month.
* Sufficient command of English to complete questionnaires.
* Patients willing to participate in the study and be randomised into one of the two study groups.
* Consulted at their general practice for type 2 diabetes in the previous 12 months.
* Residing within England (due to delivery difficulties from covid-19).
* Self-reported confirmed diagnosis of type 2 diabetes.
* Self-reported stable medication regime for diabetes for at least one month.
* Sufficient command of English to complete questionnaires.
* Patients willing to participate in the study and be randomised into one of the two study groups.
Exclusion Criteria
* Patients with type 1 diabetes.
* Patients with previous experience of using PEMF devices.
* Patients residing outside England.
* Patients with electronic implants such as pacemakers.
* Patients with an electro-cardio implant.
* Patients who have any electronic heart or lung apparatus.
* Patients who are pregnant.
* Patients who have a malignant tumour.
* Patients who are receiving high-level treatment.
* Patients who have a life-threatening illness.
* Patients with previous experience of using PEMF devices.
* Patients residing outside England.
* Patients with electronic implants such as pacemakers.
* Patients with an electro-cardio implant.
* Patients who have any electronic heart or lung apparatus.
* Patients who are pregnant.
* Patients who have a malignant tumour.
* Patients who are receiving high-level treatment.
* Patients who have a life-threatening illness.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Energy5 Limited
UNKNOWN
Sponsor Role
collaborator
St Mary's University College
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anne Majumdar
Research Administrator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Majumdar
Role: PRINCIPAL_INVESTIGATOR
St Marys University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Marys University
Twickenham, Middlesex, United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Adu MD, Malabu UH, Malau-Aduli AEO, Malau-Aduli BS. Enablers and barriers to effective diabetes self-management: A multi-national investigation. PLoS One. 2019 Jun 5;14(6):e0217771. doi: 10.1371/journal.pone.0217771. eCollection 2019.
Reference Type
BACKGROUND
Chen L, Duan X, Xing F, Liu G, Gong M, Li L, Chen R, Xiang Z. Effects of pulsed electromagnetic field therapy on pain, stiffness and physical function in patients with knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. J Rehabil Med. 2019 Dec 16;51(11):821-827. doi: 10.2340/16501977-2613.
Reference Type
BACKGROUND
Kaur S, Pandhi P, Dutta P. Painful diabetic neuropathy: an update. Ann Neurosci. 2011 Oct;18(4):168-75. doi: 10.5214/ans.0972-7531.1118409.
Reference Type
BACKGROUND
Paolucci T, Pezzi L, Centra AM, Giannandrea N, Bellomo RG, Saggini R. Electromagnetic Field Therapy: A Rehabilitative Perspective in the Management of Musculoskeletal Pain - A Systematic Review. J Pain Res. 2020 Jun 12;13:1385-1400. doi: 10.2147/JPR.S231778. eCollection 2020.
Reference Type
BACKGROUND
Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. BMJ. 2010 Mar 19;340:c1066. doi: 10.1136/bmj.c1066. No abstract available.
Reference Type
BACKGROUND
Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 2009 May;62(5):499-505. doi: 10.1016/j.jclinepi.2009.01.012.
Reference Type
BACKGROUND
Witt CM. Efficacy, effectiveness, pragmatic trials--guidance on terminology and the advantages of pragmatic trials. Forsch Komplementmed. 2009 Oct;16(5):292-4. doi: 10.1159/000234904. Epub 2009 Aug 25. No abstract available.
Reference Type
BACKGROUND
Yang X, He H, Ye W, Perry TA, He C. Effects of Pulsed Electromagnetic Field Therapy on Pain, Stiffness, Physical Function, and Quality of Life in Patients With Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Phys Ther. 2020 Jul 19;100(7):1118-1131. doi: 10.1093/ptj/pzaa054.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMU_ETHICS_2020-21_157
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study
NCT00614341
COMPLETED
PHASE4
Pulsed Electromagnetic Fields for Post-Amputation Pain
NCT05392803
COMPLETED
NA
Open Multi-center Safety & Efficacy Study of Low Frequency Magnetic Fields to Treat Unresponsive Diabetic Foot Ulcers.
NCT02145962
COMPLETED
NA
Pulsed Electromagnetic Field Versus Treadmill Walking in Peripheral Arterial Disease
NCT04621097
UNKNOWN
NA
Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy
NCT00123136
UNKNOWN
PHASE4
Interval Training and Electromagnetic Therapy on Cardiovascular Disease Risk in Diabetic Elderly
NCT06974435
COMPLETED
NA
Effect of Electromagnetic Field Therapy on Balance and Gait in Paraparetic Patients
NCT07196956
NOT_YET_RECRUITING
NA
PEMF Stimulation on Physical Exercise in Sedentary People
NCT06446466
COMPLETED
NA
P.E.M.F. Therapy of Chronic Wounds
NCT05493943
NOT_YET_RECRUITING
NA
Ultramarathons and Impact of Phased Electromagnetic Field Therapy (PEMF)
NCT03333135
COMPLETED
NA
Effect of Neuromuscular Electrostimulation on Sympathetic Nerve Activity in Patients With Type 2 Diabetes (ELECTROSYMP2)
NCT02171351
WITHDRAWN
NA
Treatment for Foot Pain Caused by Diabetic Neuropathy Using Recurrent TransCutaneous Magnetic Stimulation (TCMS)
NCT04000867
UNKNOWN
NA
Pulsed Shortwave Therapy for Postoperative Analgesia
NCT05796583
COMPLETED
NA
Effects of Pulsed Electromagnetic Fields (PEMFS) On Cerebral Haemodynamics
NCT03944993
TERMINATED
NA
The Effects of Pulsed Elelectro-Magnetic Fields ("PEMF") in the Treatment of Venous Stasis Leg Ulcers
NCT03416049
TERMINATED
TCMS for the Treatment of Foot Pain Caused By Diabetic Neuropathy
NCT03596203
COMPLETED
PHASE1
Electromagnetic Field Therapy to Improve Healing of Chronically Venous Ulcer
NCT01561170
UNKNOWN
Wireless TENS for Peripheral Edema (Lower Limb Swelling)
NCT04680533
TERMINATED
PHASE1/PHASE2
PEMF Effects on Pain After Abdominal Body Contouring
NCT01762423
WITHDRAWN
PHASE4
Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry
NCT05851430
RECRUITING
Effect of Electromagnetic Field Therapy and Customized Foot Insole on Peripheral Circulation and Ankle-Brachial Pressure Index in Patients With Diabetic Foot Ulcer
NCT07070544
NOT_YET_RECRUITING
NA
Investıgatıon of The Effıciency of Pulsed Electromagnetıc Field Therapy and Stretching Exercises
NCT05988476
COMPLETED
NA
Evaluation of Stendo Pulsating Suit on Microcirculation and Endothelial Function in Diabetic Patients
NCT02293135
UNKNOWN
NA
Effect of Pulsed Electromagnetic Field Therapy as an Adjunct Modality to Warm-up Exercise
NCT06239103
COMPLETED
NA
Effects of Pulsed Electromagnetic Field Therapy on Sport Performance and Recovery
NCT07288892
NOT_YET_RECRUITING
NA